Tenax Therapeutics, Inc.
TENX
|
$3.59
0.84%
0.84%
12K
|
Health Technology
(0.0% 1d) (-3.8% 1m) (953.3% 1y) (0.0% 2d) (0.0% 3d) (-0.8% 7d) (34.94% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 6,354,300
http://www.tenaxthera.com
Sec Filling | Patents | 9 employees
(US) Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company has a world-class scientific advisory team, including recognized global experts in pulmonary hypertension. The company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.
cardiovascular heart glass hypertension pulmonary hypertension clinical trials treatment
add to watch list Paper trade email alert is off
Press-releases
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 7.89%
H: 1.95%
C: -2.93%
first levosimendan treatment ongoing for therapeutics potential
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 1.81%
H: 7.87%
C: 7.61%
business year therapeutics financial results
Tenax Therapeutics to Present at the 36th Annual Roth Conference
Published: 2024-03-12 (Crawled : 12:30) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 0.25%
H: 0.61%
C: -0.5%
conference therapeutics
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Published: 2024-02-29 (Crawled : 14:00) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 1.69%
H: 12.35%
C: 9.03%
levosimendan presentation treatment therapeutics
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Published: 2024-02-20 (Crawled : 13:30) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 1.93%
H: 5.2%
C: -5.67%
license levosimendan global therapeutics
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: -64.03%
H: 9.16%
C: -1.17%
million offering therapeutics
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Published: 2024-02-08 (Crawled : 01:00) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: -64.03%
H: 9.16%
C: -1.17%
tnx-103 first treatment hypertension heart therapeutics study
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Published: 2024-02-06 (Crawled : 13:30) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 132.91%
H: 5.66%
C: -43.62%
patent levosimendan hypertension heart grants therapeutics
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application
Published: 2024-02-06 (Crawled : 15:00) - biospace.com/
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 132.91%
H: 5.66%
C: -43.62%
patent application grants therapeutics
Tenax Therapeutics Announces Reverse Stock Split
Published: 2023-12-29 (Crawled : 13:30) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: -1.52%
H: 1.38%
C: -15.51%
ISDR | $11.66 -1.6% -0.09% 2.4K
|
Technology Services
|
| O: 1.38%
H: 3.18%
C: 3.07%
therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Last 48 Hours Insiders Buying
CTRN P 29000 | $22.25 0.14% 0.13% 100K
|
Retail Trade
|
22:00
CONN | $3.71 1.37% 1.35% 72K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.6897 39.71% 2.3K
|
Utilities
|
18:30
CMTV P 700 | $15.74 17.43% 12K
|
Finance and Insurance
|
18:30
FNB | $13.63 2.17% 0.0% 2.5M
|
Finance
|
17:30
RMCF | $3.57 0.28% 2.8K
|
Consumer Non-Durables
|
20:10